PT-141 (Bremelanotide)
Prescription OnlyOverview
PT-141 (Bremelanotide) is a melanocortin receptor agonist. It has FDA approval in the United States under the brand name Vyleesi. In Australia, it is available as a compounded peptide through a limited number of providers.
Australian Scheduling
Schedule 4 (Prescription Only). Not individually TGA-approved but available through compounding pharmacy pathways. Stable scheduling with no anticipated changes.
Access Pathway
Limited prescription availability through select telehealth providers and clinics. 5 identified Australian providers. May also be accessible through the Personal Importation Scheme with appropriate documentation.
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.